Galmed Pharmaceuticals Ltd

詳細情報 Galmed Pharmaceuticals Ltd 企業名

Galmed Pharmaceuticals is a Israeli-based clinical-stage biopharmaceutical company.The activiti of the Company is focused on the development therapy for treating liver diseases. Arachmol, the main product of Galmed Pharmaceuticals, is a liver-targeted stearoyl-coenzyme A desaturase1 used in oral therapy for the treatment of NASH (Non-alcoholic Steatohepatitis).

企業情報

企業コードGLMD

会社名Galmed Pharmaceuticals Ltd

上場日Mar 13, 2014

最高経営責任者「CEO」Mr. Allen Baharaff

従業員数3

証券種類Ordinary Share

決算期末Mar 13

本社所在地16 Tiomkin Street

都市TEL AVIV-YAFO

証券取引所NASDAQ Capital Market Consolidated

国Israel

郵便番号6578317

電話番号97236938448

ウェブサイトhttps://www.galmedpharma.com

企業コードGLMD

上場日Mar 13, 2014

最高経営責任者「CEO」Mr. Allen Baharaff

役員一覧

会社名

会社名/ポジション

ポジション

株式保有

変動額

Mr. Allen Baharaff

President, Chief Executive Officer, Director

36.94K

+31.44%

Mr. Guy Nehemya

Chief Operating Officer, Data Protection Officer

6.28K

+20164.52%

Mr. Yohai Stenzler, CPA

Chief Accounting Officer

6.28K

+20164.52%

Mr. Doron Cohen

Chief Financial Officer

6.25K

+36664.71%

Mr. Shmuel Nir

Independent Director

3.40K

+1148.16%

Dr. David Sidransky, M.D.

Lead Independent Director

3.12K

+7338.10%

Mr. Amir Poshinski

Independent Director

3.12K

--

Dr. Carol L. Brosgart, M.D.

Independent Director

--

Mr. Marshall A. Heinberg, J.D.

Independent Director

--

Dr. Liat Hayardeny, Ph.D.

Chief Scientific Officer

--

会社名

会社名/ポジション

ポジション

株式保有

変動額

Mr. Allen Baharaff

President, Chief Executive Officer, Director

36.94K

+31.44%

Mr. Guy Nehemya

Chief Operating Officer, Data Protection Officer

6.28K

+20164.52%

Mr. Yohai Stenzler, CPA

Chief Accounting Officer

6.28K

+20164.52%

Mr. Doron Cohen

Chief Financial Officer

6.25K

+36664.71%

Mr. Shmuel Nir

Independent Director

3.40K

+1148.16%

Dr. David Sidransky, M.D.

Lead Independent Director

3.12K

+7338.10%

収益内訳

データなし

データなし

事業別

地域別

データなし

株主

更新時刻: Fri, Aug 1

株主統計

種類

株主統計

比率

Baharaff (Allen)

0.68%

Schonfeld Strategic Advisors LLC

0.46%

Virtu Americas LLC

0.20%

Two Sigma Investments, LP

0.20%

Cambridge Investment Research Advisors, Inc.

0.19%

Other

98.27%

株主統計

比率

Baharaff (Allen)

0.68%

Schonfeld Strategic Advisors LLC

0.46%

Virtu Americas LLC

0.20%

Two Sigma Investments, LP

0.20%

Cambridge Investment Research Advisors, Inc.

0.19%

Other

98.27%

種類

株主統計

比率

Individual Investor

1.20%

Hedge Fund

0.66%

Research Firm

0.20%

Investment Advisor

0.19%

Other

97.75%

機関投資家保有株

更新時刻: Tue, Jul 1

報告期間

機関投資家数

保有株式数

比率

変動額

2025Q2

36

133.14K

2.44%

+18.75K

2025Q1

40

122.99K

5.45%

+7.20K

2024Q4

44

74.98K

4.98%

+4.09K

2024Q3

46

26.83K

4.31%

-41.91K

2024Q2

47

54.30K

10.41%

+4.14K

2024Q1

52

35.65K

7.07%

-49.52K

2023Q4

54

66.85K

19.98%

-30.97K

2023Q3

59

78.73K

21.96%

+19.78K

2023Q2

57

33.03K

13.93%

-6.52K

2023Q1

63

32.53K

145.11%

-12.28K

詳細を見る

株主動向

会社名

保有株式数

比率

変動額

変動率

日付

Baharaff (Allen)

36.94K

1.64%

+8.83K

+31.44%

Mar 21, 2025

Schonfeld Strategic Advisors LLC

25.19K

1.12%

-206.00

-0.81%

Mar 31, 2025

Virtu Americas LLC

11.13K

0.49%

+11.13K

--

Mar 31, 2025

Two Sigma Investments, LP

11.02K

0.49%

+11.02K

--

Mar 31, 2025

Morgan Stanley Smith Barney LLC

7.38K

0.33%

+7.29K

+7435.71%

Mar 31, 2025

Nehemya (Guy)

6.28K

0.28%

+6.25K

+20164.52%

Mar 21, 2025

Stenzler (Yohai)

6.28K

0.28%

+6.25K

+20164.52%

Mar 21, 2025

Cohen (Doron)

6.25K

0.28%

+6.23K

+36664.71%

Mar 21, 2025

Nir (Shmuel)

3.40K

0.15%

+3.12K

+1148.16%

Mar 21, 2025

詳細を見る

1.630USD

Galmed Pharmaceuticals Ltd

1.630

概要

企業名

金融